Healthy Returns: Medicaid cuts in Trump's megabill may affect some drugmakers more than othersCNBC • 07/08/25
Vertex Pharmaceuticals (VRTX) Rises As Market Takes a Dip: Key FactsZacks Investment Research • 07/01/25
Vertex Announces European Commission Approval of ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic FibrosisBusiness Wire • 07/01/25
Vertex Down Around 9% in Three Months: Should You Buy, Sell or Hold the Stock?Zacks Investment Research • 06/30/25
Vertex and Ono Pharmaceutical Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South KoreaBusiness Wire • 06/23/25
Vertex Pharmaceuticals Incorporated (VRTX) Presents at American Diabetes Association (ADA) 85th Scientific Sessions Conference TranscriptSeeking Alpha • 06/23/25
Vertex Presents Positive Data for Zimislecel in Type 1 Diabetes at the American Diabetes Association 85th Scientific SessionsBusiness Wire • 06/20/25
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Goldman Sachs 46th Annual Global Healthcare Conference TranscriptSeeking Alpha • 06/10/25
Vertex Presents New Data on Benefits of ALYFTREK® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis ConferenceBusiness Wire • 06/06/25
Vertex Pharmaceuticals Incorporated (VRTX) Bernstein 41st Annual Strategic Decisions Conference (Transcript)Seeking Alpha • 05/30/25